RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$17.56 (−53.82%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Ultragenyx Pharmaceutical Inc. grew revenue 17.5% to $717.21M over the twelve months to Jun 30, 2026. Free cash flow was -$489.00M.
Revenue
$717.21M
+17.5% vs. a year earlier
Operating income
-$528.17M
TTM Q2 2026
Free cash flow
-$489.00M
TTM Q2 2026
EPS, diluted
-$5.84
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.54B
- P/E ratio
- –
- Price to sales
- 2.14
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -31.84%
Fundamentals
- Revenue
- $717.21M
- Net income
- -$585.97M
- EPS, diluted
- -$5.84
- Free cash flow
- -$489.00M
- Book value per share
- -$2.86
- Diluted shares
- 102M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$717.21M+17.5% YoY
Gross profit
–
Operating income
-$528.17M
Net income
-$585.97M
EPS, diluted
-$5.84
Free cash flow
-$489.00M
Reported periodTrailing twelve months